Current Regulatory Challenges in conduct of Clinical Trials –India

Current Regulatory Challenges in
conduct of Clinical Trials –India​
Prabhat Kumar
November 2014
• Clinical Trial current regulatory framework
• Current regulatory challenges
• Background of evolution of current regulatory
• Recommendation of the expert committee
• Actions from the CDSCO
• Industries expectations
• Positive developments….!
• Way forward
Clinical Trials: Current Regulatory Framework 1
Drugs and Cosmetics Act,1940 & Rules,1945
ICMR Ethical guidelines,2000/2006
Indian GCP Guidelines, 2001
National Pharma.Vig. Programme, 2004
Revised Schedule Y (Drugs & Cosmetics Rules),
Clinical Trials: Current Regulatory Framework 2
BA/BE Study Guidelines, 2005
Notification on Devices,2005
Amendment to Drugs and Cosmetic Act,2008
Notification on Clinical trial registration, 2009
Amendment to D and C Act, CRO Regn,Sch.Y1,2009
• Proposed Clinical establishment Bill,2010
• Amendments in 2012 and 2013
• CDSCO official order/notifications………..
Background of evolution of current
regulatory framework
• NHRC orders probe into southern state drug trial scandal – several
women were as used as human subject for breast cancer drug trial by a
pharmaceutical company.
• Unauthorised clinical trial of vaccine against cervical cancer were
conducted by an NGO on 25,000 minor girls in one of the southern
states and in western state.(HPV Vaccine Trial) A government funded
hospital in Bhopal was conducting clinical trials on unwitting patients.
• A Medical College in Indore enrolled children for illegal drug tests for
nearly ten years.
• Health activists are concerned about the way many clinical trials are
conducted in this country.
• There have been a series of incidences involving alleged malpractices in
recent past, health minister in last govt. talked in Parliament about
patient deaths during clinical trials.
Background of evolution……framework .Cont..
Expert Committee by MoH under Dr. Ranjit Roy choudhury
Term of reference : To formulate policy and guidelines for
–Approval of new drugs including biologicals
–Approval of clinical trials including global CTs, BA/BE studies for export
–Functioning of the 12 NDACs (now replaced with SEC and TEC)
–To identify experts for the CDSCO
–Any other matter related to CDSCO
Recommendation of the expert committee
• Total 25 recommendations were suggested by this
committee which includes…
CTs can be conducted only at accredited Clinical sites by accredited PIs after
approval by accredited ECs.
Roster of experts (SEC) from all over India and selection of experts by random
Roster of accredited sites from which Pharma co.s can select the Sites and PIs.
A technical review Committee to be set up to take uniform, unbiased ,final
decision on approvals.
Audio-visual recording wherever necessary in vulnerable groups.
Compensation (Financial) to be paid to legal nominees in case of Death or
All SAEs to get equal treated whether due to test drug, placebo or Standard
Provision of Ancillary care during trial period.
Actions from the CDSCO
• CDSCO office released a series of orders (total 14) with
regard to requirements for conduct/ approval of clinical
trials and new drug approval based on the
recommendations of R.R. Committee Report.
Which includes mainly…….
• CT Compensation in case of injury or death discerned at
a later stage.
• Providing Ancillary Care to the Clinical Trial subjects
• Limiting Number of Clinical Trials an investigator can
undertake at a time
Action…… continued…
• Requirement for filing of application to market
new Chemical
• Waiver of CT in Indian Population for approval of
New Drugs
• Requirement for filing of application to market
new Chemical Entities
Industries expectations
Need of the clarity
• Expectation to have consolidated guidance
documents providing the current interpretation
of the regulations related to the EC functioning,
(similar to USFDA, EMEA etc. )
Industries expectations
Clinical trial liabilities
• Recently DCGI has been instructing sponsors /CROs to
include the wording in ICF that sponsor or CRO will provide
complete medical care as well as compensation for the injury.
• The injury may either arise out of the ‘study’ i.e. as specified
in the Protocol and the ICF or may arise out of any act,
omission, negligence or misconduct of the CRO or the
investigator / institution.
• Who would primarily be liable to compensate the study
subject, whether the sponsor or the CRO or the investigator /
institution in connection with the study?
Industries expectations
Access to drugs
• Another issue that arises is the liability of the
sponsor to provide access to drugs and treatment
post termination of the trial. Depending upon the
study protocol, availability of the drug and stage
of the trial, this issue needs to be addressed.
Positive developments….!
In the recent(Oct14) DIA conference, where some
of the regulatory challenges were discussed and
thoughts from the stake holders
There are upcoming positive changes in the near
future in the areas of:
Clinical trial conduct:
• Accreditation will be required for Investigators/Study sites
to conduct clinical trials.
• Accreditation of Ethics Committee/Institutional Review
Board to approve/oversee clinical trials.
Positive developments….! Conti……
• Compensation clause for any injury to subjects participating
in trials: This is being re-visited (no compensation for
ineffective therapy or adverse events not related to drug, or
adverse events for patients in placebo arm are being
• Audio-visual recording of informed consent (IC) is being
– Regulatory system: Transparency and possibility of
online tracking of regulatory application are being
worked up on.
– Changes in medical/nursing education system.
– Affordable health: Health assurance for all patients at
primary health centers; health insurance for
Way forward
• There are encouraging sentiments of upcoming positive
changes in the regulatory environment will lead to more
clinical trial work in India.
• With the advent of globalization, it is important to
adhere to global standards and best practice respecting
local norms and value at the same time look at
innovative ways to provide affordable healthcare to
patients in India.
• Collaborative work is required between regulators,
industry and academia to support innovation .
• Regulatory frame work must be rational and evidencebased; rather mere opinion based.
Over Regulation?
Controlled regulation: Win-Win situation !!!
The views and opinions expressed in the following PowerPoint slides are those of
the individual presenter and should not be attributed to my organisation, its
directors, officers, employees, volunteers, members, committee, or affiliates, or
any organization with which the presenter is employed or affiliated.
Many THANKS for YOUR Attention
Dziękuję Ďakujem dhanya-waad ధన్యవాదాలు
bedankt ありがとう go raibh maith agat
tesekkürle Спасибо ‫شكرا‬
Thank yu
Merci köszi tack så mycket
Thank hvala
Shukriyâ Danke
díky kiitos
takk Obrigada
Mulţumesc nandri
Ευχαριστώ Grazie anugurihiitosumi ‫תודה‬
Muchas gracias dhanya-waad
너를 감사하십시요 ačiû Terima Kasih
aitäh děkuji vam mange tak salamat